Intravitreal injections (IVT) is the common treatment for the posterior segment of eye diseases. IVT is an invasive route of administration that requires regular visits to the clinic for patients to receive the injection by the doctors. IVT as the medical procedure itself can potentially cause multiple side effects and complications, not to mention patient discomfort and non-compliance.

At Alephoson, we have been developing and optimising a novel drug delivery platform, cell penetrating peptide (aCPP). After topical instillation in animals, a rapid and wide distribution of aCPP in both the anterior and posterior segment of the eye could be observed on the corneal epithelium and retina sites.

Advancing ophthalmic drug delivery by utilizing proprietary and patented Cell Penetration Protein Alternation (CePPA) Technology^TM to treat chronic eye diseases including both anterior and posterior part of the eye.

Our lead candidate CPB202, a topical biologic eye-drop, provides a safer and unprecedented therapy to overcome the limitations of the current intravitreal injection treatment for sight-threatening eye diseases, including but not limited to neovascular age-related macular degeneration (nAMD). Alephoson has a compelling pipeline including biologics, small molecules, and gene therapy.